Jun 17, 2026 09:25AM
Jun 9, 2026 09:25AM
Jun 9, 2026 09:25AM
Jun 3, 2026 09:25AM
May 19, 2026 09:15AM
May 7, 2026 09:25AM
May 5, 2026 09:11AM Lexaria advances human study testing oral semaglutide formulations
May 5, 2026 09:10AM
May 1, 2026 09:25AM
Apr 29, 2026 09:10AM
Apr 29, 2026 09:10AM
Apr 23, 2026 09:05AM
Apr 21, 2026 09:10AM
Apr 15, 2026 09:10AM Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Apr 7, 2026 09:10AM
Apr 7, 2026 09:10AM
Apr 1, 2026 09:20AM
Apr 1, 2026 09:20AM
Mar 26, 2026 09:20AM
Mar 26, 2026 09:20AM
Mar 24, 2026 09:15AM Lexaria in talks with pharma companies for oral GLP-1 drug development
Mar 24, 2026 09:15AM
Mar 4, 2026 09:25AM
Mar 4, 2026 09:25AM
Feb 5, 2026 09:15AM
Jan 22, 2026 09:22AM
Jan 22, 2026 09:20AM
Jan 12, 2026 09:10AM Lexaria Bioscience CEO outlines 2025 progress and 2026 plans
Jan 12, 2026 09:10AM
Dec 30, 2025 09:20AM
Dec 30, 2025 09:20AM
Dec 23, 2025 09:29AM
Dec 23, 2025 09:29AM
Dec 16, 2025 04:00PM
Dec 16, 2025 04:00PM Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Dec 15, 2025 08:01AM
Dec 15, 2025 08:00AM
Nov 12, 2025 09:11AM
Nov 12, 2025 09:10AM
Oct 9, 2025 09:20AM
Oct 9, 2025 09:20AM
Sep 29, 2025 04:30PM Lexaria Bioscience closes $4 million registered direct offering
Sep 29, 2025 04:30PM
Sep 26, 2025 08:00AM
Sep 26, 2025 08:00AM
Sep 19, 2025 11:25AM
Sep 19, 2025 11:20AM
Aug 27, 2025 09:20AM
Aug 14, 2025 09:20AM Lexaria completes patient dosing in Phase 1b GLP-1 study
Aug 14, 2025 09:20AM

323,686 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All